DOI: 10.1128/AAC.02097-16
Article Information
PubMed
Published By
History
- Received September 28, 2016
- Returned for modification November 16, 2016
- Accepted November 18, 2016
- Published online February 23, 2017.
Copyright & Usage
Copyright © 2017 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (December 28, 2016).
- You are viewing the most recent version of this article.
Author Information
- Ryan K. Shieldsa,b,
- Liang Chenc,
- Shaoji Chenga,
- Kalyan D. Chavdac,
- Ellen G. Pressa,
- Avin Snydera,
- Ruchi Pandeyc,
- Yohei Doia,
- Barry N. Kreiswirthc,
- M. Hong Nguyena,b and
- Cornelius J. Clancya,b,d
- aDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
- bXDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
- cPublic Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA
- dVA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA
- Address correspondence to M. Hong Nguyen, mhn5{at}pitt.edu.
R.K.S. and L.C. contributed equally to this paper.
M.H.N. and C.J.C. contributed equally to this paper.
Citation Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
